Avadel pharmaceuticals investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of avadel pharmaceuticals plc - avdl

New york city & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of avadel pharmaceuticals plc (nasdaqgm: avdl) to alkermes plc (nasdaqgs: alks). under the terms of the proposed transaction, shareholders of avadel will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per s.
AVDL Ratings Summary
AVDL Quant Ranking